Form 4 for TLSI TriSalus Life Sciences, Inc.

Accepted 2026-04-20 16:36:46 ET · period of report 2025-07-31 · accession 0001628280-26-026014 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-04-20 16:36	2025-07-31	TLSI	Frankenius Equity AB	10%	C - Cnv Deriv	$0.00	+759.0K	6.99M	+12%	$0
D	2026-04-20 16:36	2025-07-31	TLSI	Frankenius Equity AB	10%	C - Cnv Deriv	$0.00	-230.0K	0	-100%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-07-31	C	A	759,000	$0.00	6,989,748	D	—	—	(F1) Represents shares received upon conversion of the Series A Preferred Stock (the "Preferred Stock") reported in Table II.
2	Derivative	Series A Convertible Preferred Stock	2025-07-31	C	D	230,000	$0.00	0	D	$4.00 · — to —	759,000 Common Stock	(F2) Represents conversion price pursuant to an offer (the "Offer") the Company commenced on June 23, 2025, under which all holders of Preferred Stock could exchange their shares of Preferred Stock for Common Stock equal to the sum of the liquidation preference per share price of $10.00 and all accrued and unpaid dividends per share outstanding through August 10, 2027, divided by a $4.00 conversion price per share. (F3) On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer. (F3) On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer. (F3) On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer.